02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Bimatoprost SR: Interim Phase I/II data

Interim data from a 24-month Phase I/II trial in 75 patients with open-angle glaucoma or ocular hypertension showed that a single dose of 6, 10, 15 and 20 ug bimatoprost SR given via an intracameral...